Effects of Colesevelam HCl On Bile Acid Kinetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-05-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

NCT01122108

Healthy

COMPLETED PHASE4

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

NCT00488449

Healthy Subjects Dyslipidaemias

COMPLETED PHASE1

Colesevelam, Lipids And Sugars, South Asian Canadian Trial

NCT02504736

Dyslipidemia

COMPLETED

Cholesterol Metabolism and Lipid Transfer in Diabetes

NCT01010035

Type 2 Diabetes Mellitus

COMPLETED

A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

NCT02087917

Primary Hypercholesterolemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bile acids, which are synthesized from cholesterol in the liver, play a key role in digestion as they solubilize dietary lipids and aid their absorption in the digestive tract. While for many years bile acids have been characterized by this digestive role, recent research indicates that bile acids play other important roles. Because bile acids have been shown to act in signaling pathways that affect metabolism, there has been renewed interest in investigations of their effects. This study explores potential differences in bile acid kinetics based on insulin resistance or type 2 diabetes at baseline.

Colesevelam HCl is a bile acid sequestrant, which in addition to its primary role in lowering serum LDL-C levels, has secondarily been implicated in lowering blood glucose levels. This study explores the relationship between insulin resistance and type 2 diabetes and changes in bile acid pool sizes and kinetics with colesevelam treatment. Isotopically labeled bile acids will be administered to subjects before and after treatment with colesevelam and comparisons will be made in bile acid pool size, fractional turnover rate, and synthesis rate in the three study groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Impaired Glucose Tolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Glucose Metabolism

Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl

Colesevelam HCl

Intervention Type DRUG

Impaired Glucose Tolerance

Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl

Colesevelam HCl

Intervention Type DRUG

Frank type 2 diabetes

Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl

Colesevelam HCl

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colesevelam HCl

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have given written informed consent
* BMI 25-35 kg/m\^2, inclusive
* Normal liver and thyroid function
* No history of liver, biliary, or intestinal disease

Diabetic Subjects

* Diagnosed Type 2 Diabetes Mellitus
* HbA1C = 6.7-10%

Normal Subjects

* 2 hr OGTT glucose \< 140 mg/dL
* fasting glucose \< 100 mg/dL
* TG \< 150 mg/dL
* HDL cholesterol \>= 40 mg/dL

Impaired Glucose Tolerance Subjects

* 2 hr OGTT glucose \>= 140 and \< 200 mg/dL

Exclusion Criteria

* T1DM or history of diabetic ketoacidosis
* treatment with blood pressure lowering therapy that has not been stable for three months before screening
* colesevelam HCl, cholestyramine, or colestipol treatment for hyperlipidemia within the last three months
* treatment with thiazolidinedione (TZD) at any time
* treatment with insulin within past 6 months
* treatment with antibiotics within last 3 months
* extreme sportsmen
* treatment with medication affecting liver or intestinal function within the last 3 months
* allergic or toxic rxn to colesevelam HCl
* history of dysphagia, swallowing disorders, or intestinal motility disorder
* Serum Triglycerides \> 500 mg/dL at visit 1
* Serum LDL-C \< 60 mg/dL at visit 1
* any condition or therapy investigator believes not in subjects best interest
* use of any investigational drug within 30 days before screening
* chronic treatment with oral corticosteroids at any time or acute treatment within last three months
* hyperthyroidism or treatment with thyroid hormone/levothyroxine

Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes